See more : Hind Aluminium Industries Limited (HINDALUMI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Tango Therapeutics, Inc. (TNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tango Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oriental Shiraishi Corporation (1786.T) Income Statement Analysis – Financial Results
- Shreyas Shipping and Logistics Limited (SHREYAS.NS) Income Statement Analysis – Financial Results
- Water Oasis Group Limited (WOSSF) Income Statement Analysis – Financial Results
- Sidney Resources Corp. (SDRC) Income Statement Analysis – Financial Results
- Colicity Inc. (COLIW) Income Statement Analysis – Financial Results
Tango Therapeutics, Inc. (TNGX)
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Cost of Revenue | 115.20M | 4.03M | 1.97M | 1.63M | 32.27M |
| Gross Profit | -78.67M | 20.83M | 35.08M | 6.03M | -7.63M |
| Gross Profit Ratio | -215.38% | 83.80% | 94.69% | 78.77% | -30.93% |
| Research & Development | 115.20M | 105.91M | 77.64M | 49.99M | 32.27M |
| General & Administrative | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Other Expenses | 0.00 | 2.95M | 247.00K | 120.00K | 0.00 |
| Operating Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 7.15M |
| Cost & Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 39.43M |
| Interest Income | 6.62M | 1.46M | 495.00K | 108.00K | 684.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.42M | 4.03M | 1.97M | 1.63M | 643.00K |
| EBITDA | -111.76M | -109.46M | -57.29M | -51.48M | -14.52M |
| EBITDA Ratio | -305.96% | -446.79% | -157.09% | -672.44% | -58.90% |
| Operating Income | -114.17M | -111.07M | -58.19M | -52.20M | -15.16M |
| Operating Income Ratio | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Total Other Income/Expenses | 12.56M | 2.95M | 247.00K | 228.00K | 1.07M |
| Income Before Tax | -101.61M | -108.12M | -57.94M | -51.97M | -14.10M |
| Income Before Tax Ratio | -278.18% | -434.92% | -156.43% | -678.84% | -57.18% |
| Income Tax Expense | 134.00K | 54.00K | 292.00K | -108.00K | 0.00 |
| Net Income | -101.74M | -108.18M | -58.24M | -51.86M | -14.10M |
| Net Income Ratio | -278.54% | -435.14% | -157.21% | -677.43% | -57.18% |
| EPS | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Weighted Avg Shares Out | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
| Weighted Avg Shares Out (Dil) | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
Tango Therapeutics to stop development of cancer therapy
Tango Therapeutics said on Thursday it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial.
Tango Therapeutics Announces Discontinuation of TNG348 Program
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority...
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.
Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a...
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business...
Tango Therapeutics to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate...
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium...
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of...
Source: https://incomestatements.info
Category: Stock Reports